The therapeutic scheme for 177Lu-PSMA therapy involves 4–6 therapy cycles with fixed activities (7), whereas optimal patient treatment would consider individual factors during RPT planning, such as weight, height, tumor burden, pretreatments, dosimetry, and patients’ preferences (8). The gene discussed is FOLH1; the disease is neoplasm.